STOCK TITAN

Bioxytran Inc - BIXT STOCK NEWS

Welcome to our dedicated news page for Bioxytran (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioxytran's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioxytran's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
covid-19
Bioxytran Inc

OTC:BIXT

BIXT Rankings

BIXT Stock Data

19.48M
47.16M
59.59%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Newton Upper Falls

About BIXT

bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.